NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Thursday that its fourth quarter revenues rose 4 percent year over year, thanks to an increase in revenues from its clinical laboratory services business.

For the three-month period ended July 31, the molecular diagnostics company reported revenues of $26.6 million, up from $25.7 million a year earlier.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.